ROS1 and non-small cell lung carcinoma: The Food and Drug Administration of the United States has approved crizotinib for advanced non-small cell lung cancer with ALK or ROS1 fusion.13 Response to crizotinib has been documented in case reports of patients with lung adenocarcinoma with MET fusion.